In-Depth Serum Proteomics Reveals the Trajectory of Hallmarks of Cancer in Hepatitis B Virus–Related Liver Diseases

• DOI: 10.1016/j.mcpro.2023.100574
• Publication Date: 2023-05-19T07:03:52Z
• Authors: Meng Xu; Kaikun Xu; Shangqi Yin; Cheng Chang; Wei Sun; Guibin Wang; Kai Zhang; Jinsong Mu; Miantao Wu; Baocai Xing; Xiaomei Zhang; Jinyu Han; Xiaohang Zhao; Yajie Wang; Danke Xu; Xiaobo Yu
• Keywords: Liver Cancer; Biomarker Discovery; Proteome; Hepatitis B

Hepatocellular carcinoma (HCC) is a prevalent cancer in China, with chronic hepatitis B (CHB) and liver cirrhosis (LC) being high-risk factors for developing HCC. Here, we determined the serum proteomes (762 proteins) of 125 healthy controls Hepatitis virus-infected CHB, LC, HCC patients constructed first cancerous trajectory diseases. The results not only reveal that majority altered biological processes were involved hallmarks (inflammation, metastasis, metabolism, vasculature, coagulation) but also identify potential therapeutic targets pathways (i.e., IL17 signaling pathway). Notably, biomarker panels detecting CHB LC populations further developed using machine learning two cohorts comprised 200 samples (discovery cohort = validation 75). protein signatures significantly improved area under receiver operating characteristic curve (CHB discovery 0.953 0.891, respectively; 0.966 0.818, respectively) compared to traditional biomarker, alpha-fetoprotein, alone. Finally, selected biomarkers validated parallel reaction monitoring mass spectrometry an additional (n 120). Altogether, our provide fundamental insights into continuous changes biology diseases candidate early detection intervention.